Brookstone Capital Management Acquires 53,876 Shares of Boston Scientific Corporation $BSX

Brookstone Capital Management boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,197 shares of the medical equipment provider’s stock after acquiring an additional 53,876 shares during the quarter. Brookstone Capital Management’s holdings in Boston Scientific were worth $17,468,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. State Street Corp grew its position in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the period. Invesco Ltd. increased its holdings in Boston Scientific by 0.7% during the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after purchasing an additional 111,826 shares in the last quarter. Northern Trust Corp grew its stake in shares of Boston Scientific by 0.9% during the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after acquiring an additional 128,188 shares in the last quarter. Finally, Amundi grew its holdings in shares of Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after acquiring an additional 1,781,830 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific’s Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

BSX stock opened at $62.90 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a 1 year low of $61.24 and a 1 year high of $109.50. The company’s 50-day moving average is $76.94 and its 200-day moving average is $90.32. The stock has a market capitalization of $93.49 billion, a PE ratio of 32.42, a price-to-earnings-growth ratio of 1.07 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on BSX shares. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $97.00 price target on shares of Boston Scientific in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.